In the study, we showed the clinical relevance of S100A9+ MDSCs and TAMs in terms of microenvironment-mediated resistance to EGFR-TKIs in the setting of lung adenocarcinoma harboring activating EGFR mutations and linked the circulating S100A9+ MDSCs to tumor microenvironment. Here, EGFR is linked to lung adenocarcinoma.